JP3228534B2 - Composition for lowering blood alcohol concentration - Google Patents

Composition for lowering blood alcohol concentration

Info

Publication number
JP3228534B2
JP3228534B2 JP24675791A JP24675791A JP3228534B2 JP 3228534 B2 JP3228534 B2 JP 3228534B2 JP 24675791 A JP24675791 A JP 24675791A JP 24675791 A JP24675791 A JP 24675791A JP 3228534 B2 JP3228534 B2 JP 3228534B2
Authority
JP
Japan
Prior art keywords
ethanol
extract
alcohol concentration
composition
panax ginseng
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP24675791A
Other languages
Japanese (ja)
Other versions
JPH05170659A (en
Inventor
長八 今野
裕 鈴木
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nitto Denko Corp
Original Assignee
Nitto Denko Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corp filed Critical Nitto Denko Corp
Priority to JP24675791A priority Critical patent/JP3228534B2/en
Publication of JPH05170659A publication Critical patent/JPH05170659A/en
Application granted granted Critical
Publication of JP3228534B2 publication Critical patent/JP3228534B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【産業上の利用分野】本発明は組織培養オタネニンジン
の抽出物のエタノール不溶物を有効成分とする血中アル
コール濃度低下用組成物に関する。当該組成物は医薬
品、食品(特に機能性食品)等として有用である。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a composition for lowering blood alcohol concentration, comprising an ethanol-insoluble extract of a tissue culture panax ginseng as an active ingredient. The composition is useful as a medicine, food (especially functional food) and the like.

【0002】[0002]

【従来技術】経口的に摂取(飲酒)したアルコールは消
化管から吸収されて血中に入り、主として肝臓で代謝さ
れる。代謝は肝臓内アルコール脱水素酵素系とミクロゾ
ーム・エタノール酸化系で起こり、いずれも酸化されて
アセトアルデヒドを生成する。この生成したアセトアル
デヒドは生体に対して種々の有害作用を示し、顔面紅
潮、心拍数増加、頭痛、眠気、吐気、アレルギー症状、
悪酔い、二日酔い、ひいては肝炎を引き起こす。このア
セトアルデヒドは肝臓でアセトアルデヒド脱水素酵素に
より酢酸に代謝されるが、この酵素の活性が低いかまた
は血中アルコール濃度が高い場合にはアセトアルデヒド
の蓄積が起こり上記の有害作用に起因する中毒を起こす
ことがある。そこでアルコール飲料を摂取しても上記の
如き症状の生起を少なくするためには、血中のアルコー
ル濃度を低下させる物質もしくはアセトアルデヒドの代
謝を促進する物質、アセトアルデヒドの毒性を軽減する
物質を摂取すればよいと考えられる。
2. Description of the Related Art Alcohol taken orally (drinked) is absorbed from the digestive tract, enters the blood, and is metabolized mainly by the liver. Metabolism occurs in the liver alcohol dehydrogenase system and the microsomal ethanol oxidation system, both of which are oxidized to produce acetaldehyde. The produced acetaldehyde has various adverse effects on the living body, such as hot flushes, increased heart rate, headache, drowsiness, nausea, allergic symptoms,
Causes sickness, hangover, and hepatitis. This acetaldehyde is metabolized to acetic acid by acetaldehyde dehydrogenase in the liver.If the activity of this enzyme is low or the blood alcohol concentration is high, acetaldehyde accumulates and causes poisoning due to the above harmful effects. There is. Therefore, in order to reduce the occurrence of the symptoms as described above even when ingesting alcoholic beverages, a substance that lowers the alcohol concentration in the blood or a substance that promotes metabolism of acetaldehyde or a substance that reduces the toxicity of acetaldehyde can be obtained. It is considered good.

【0003】このような物質としては、アセトアルデヒ
ドトラップ剤としてD−ペニシラミン(文献1)、L−
システイン、DL−ホモシステインなどのSH化合物、
ビタミンB1 とその誘導体およびアスコルビン酸(文献
2)、L−メチオニン(文献3)が、代謝促進剤として
卵白加水分解物(各種アミノ混合物)(文献4)が、毒
性軽減剤としてL−a−アラニン(文献5)が、アルコ
ール吸収抑制剤としてグリシル・グリシン(文献6)が
知られている。
[0003] Such substances include D-penicillamine (Reference 1) and L-
SH compounds such as cysteine and DL-homocysteine,
Vitamin B 1 and its derivatives and ascorbic acid (Reference 2), L-methionine (Document 3), egg white hydrolyzate as a metabolic enhancer (various amino mixture) (Reference 4), L-a- as toxicity-reducing agent Alanine (Reference 5) and glycyl-glycine (Reference 6) are known as alcohol absorption inhibitors.

【0004】一方、オタネニンジン(Panax ginseng C.
A. Meyer)の根から調製される人参には薬効としては、
強壮、強精、胃腸機能増進などが知られている。また、
人参はアルコールの長期投与による肝炎を抑制すること
が報告されている(文献7)。さらに、血中アルコール
濃度低下作用が知られている(文献8)。
On the other hand, Panax ginseng C.
A. Meyer)
It is known for its tonic, tonic, and gastrointestinal functions. Also,
Ginseng has been reported to suppress hepatitis due to long-term administration of alcohol (Reference 7). Further, a blood alcohol concentration lowering effect is known (Reference 8).

【0005】ところが、文献8は、単に人参エキスの血
中アルコール濃度低下作用を記載するに止まるものであ
り、その作用もあまり強いものではない。また、人参は
天産物であるためにその効果にはばらつきが生ずる。
[0005] However, Literature 8 merely describes the blood alcohol concentration lowering effect of ginseng extract, and the effect is not very strong. Ginseng is a natural product, and its effects vary.

【0006】[0006]

【発明が解決しようとする課題】本発明の目的は安定的
かつ強力な血中アルコール濃度低下用組成物を提供する
ことである。
SUMMARY OF THE INVENTION An object of the present invention is to provide a stable and powerful composition for lowering blood alcohol concentration.

【0007】[0007]

【課題を解決するための手段】上記目的を達成するため
に、発明者らは鋭意研究を行った結果、組織培養オタネ
ニンジン抽出物のエタノール不溶物が再現性の良い、し
かも極めて優れた血中アルコール濃度低下作用を有する
ことを見出し、さらに研究を重ねて本発明を完成するに
至った。即ち、本発明は組織培養オタネニンジンの抽出
物のエタノール不溶物を含有してなる血中アルコール濃
度低下用組成物である。
Means for Solving the Problems In order to achieve the above object, the present inventors have conducted intensive studies, and as a result, it has been found that an ethanol-insoluble substance of a tissue culture panax ginseng extract has a reproducible and extremely excellent blood alcohol. The present inventors have found that they have a concentration lowering effect, and have conducted further studies to complete the present invention. That is, the present invention is a composition for lowering blood alcohol concentration, which comprises an insoluble ethanol extract of a tissue culture panax ginseng extract.

【0008】本発明で使用される組織培養オタネニンジ
ンの由来には特に制限はなく、日本産、韓国産、中国産
などのいずれに由来するものであってもよい。組織培養
オタネニンジンの製造方法は、自体既知の方法に従えば
よく、例えば特公昭60−4713号公報、特公昭63
−21470号公報に記載の方法またはこれに準ずる方
法が例示される。
[0008] The origin of the tissue-cultured Panax ginseng used in the present invention is not particularly limited, and may be derived from any of Japan, Korea, China and the like. The method of producing the tissue culture panax ginseng may be in accordance with a method known per se, for example, JP-B-60-4713, JP-B-63.
A method described in JP-A-21470 or a method analogous thereto is exemplified.

【0009】本発明に関して、組織培養オタネニンジン
の抽出物は、通常極性溶媒、好ましくは高極性溶媒によ
る抽出物であるが、本発明の組成物が食品(特に機能性
食品)、医薬品などに用いられることを考慮すれば、好
ましくは水性溶媒による抽出物である。水性溶媒として
は、水単独または水とエタノールとの任意の割合の混合
溶媒が好都合に使用される。ここに水とエタノールとの
混合割合は、通常20:80〜100:0、好ましくは
50:50である。抽出時には、常温以上100℃以下
の範囲に加温することによって抽出効率がより一層向上
する。
In the present invention, the extract of tissue culture Panax ginseng is usually an extract with a polar solvent, preferably a highly polar solvent, but the composition of the present invention is used for foods (particularly functional foods), pharmaceuticals and the like. Considering that, the extract is preferably an aqueous solvent-based extract. As the aqueous solvent, water alone or a mixed solvent of water and ethanol at any ratio is conveniently used. Here, the mixing ratio of water and ethanol is usually 20:80 to 100: 0, preferably 50:50. At the time of extraction, the extraction efficiency is further improved by heating to a range of room temperature to 100 ° C.

【0010】組織培養オタネニンジンの抽出物のエタノ
ール不溶物は、上記の抽出物をエタノールと混合した時
に生じる沈殿である。当該エタノール不溶物は、例えば
次のようにして調製される。即ち、上記で得た抽出液
を、好適には通常の方法で濃縮乾燥し、さらにその乾燥
物を少量の水に溶解した後、エタノールを加え攪拌し通
常の方法で濾過し、沈澱を集めることによって調製され
る。この方法はエタノール沈澱法と呼ばれ、この方法に
おいては、当該抽出物の乾燥物を機械的にまたは超音波
で粉砕した後、少量の水に溶解した後、エタノールを加
えることが効率的である。
The ethanol-insoluble matter of the extract of tissue culture Panax ginseng is a precipitate formed when the above extract is mixed with ethanol. The ethanol-insoluble matter is prepared, for example, as follows. That is, the extract obtained above is preferably concentrated and dried by a usual method, and further, after dissolving the dried product in a small amount of water, adding ethanol, stirring and filtering by a usual method, and collecting a precipitate. Prepared by This method is called an ethanol precipitation method. In this method, it is efficient to pulverize the dried product of the extract mechanically or by ultrasonication, dissolve it in a small amount of water, and then add ethanol. .

【0011】本発明の組成物は、食品用途として、機能
食品、食品添加物などとして有用である。また、本発明
の組成物は、人をはじめとする哺乳動物に対する血中ア
ルコール濃度低下剤などの医薬として有用である。
The composition of the present invention is useful for food applications, functional foods, food additives and the like. Further, the composition of the present invention is useful as a drug such as a blood alcohol concentration lowering agent for mammals including humans.

【0012】本発明の組成物は、上記沈殿物としてその
まま態様で摂取してもよいが、摂取時の容易さ、加工の
容易さを考慮すると、凍結乾燥などによって一旦微粉末
状にすることが好ましい。また、本発明の組成物は、自
体既知の添加剤(担体、賦形剤、増量剤、安定化剤、矯
味剤、香料、他の医薬成分など)とともに、たとえば飲
料、粉末状食品、錠剤、顆粒剤、液剤、粉末剤、カプセ
ル剤などに成形化、製剤化してもよい。
The composition of the present invention may be ingested as it is in the form of the above-mentioned precipitate. However, in consideration of ease of ingestion and easiness of processing, it may be once converted into a fine powder by freeze-drying or the like. preferable. In addition, the composition of the present invention may be used together with additives (carriers, excipients, bulking agents, stabilizers, flavoring agents, flavors, other pharmaceutical ingredients, etc.) known per se, for example, beverages, powdered foods, tablets, It may be formed into granules, liquids, powders, capsules and the like, and formulated.

【0013】本発明の有効成分である組織培養オタネニ
ンジンの抽出物のエタノール不溶物の血中アルコール濃
度低下作用を得るための摂取量は、これを摂取する人の
体重、体質などによる個人差が大きく明確に特定できな
いが、通常一回摂取量は出発物質である組織培養オタネ
ニンジンに換算した場合は0.1〜10gの範囲、好ま
しくは0.3〜3gの範囲にあることが望ましい。ま
た、抽出物のエタノール不溶物としては0.2〜5gの
範囲が望ましい。
The amount of ethanol-insoluble extract obtained from the extract of tissue culture panax ginseng, which is an active ingredient of the present invention, for obtaining the effect of lowering the alcohol concentration in blood varies greatly depending on the weight and constitution of the person who takes the extract. Although not clearly specified, it is generally desirable that the single dose is in the range of 0.1 to 10 g, preferably 0.3 to 3 g, when converted into the tissue culture panax ginseng as a starting material. The extract is preferably insoluble in ethanol in the range of 0.2 to 5 g.

【0014】また、本発明の血中アルコール濃度低下用
組成物の摂取時期については特に限定はなく、アルコー
ル摂取前または摂取と同時に当該組成物を摂取すること
によって悪酔いや二日酔いの予防することができ、また
アルコール摂取後に摂取して悪酔いや二日酔いを抑制す
ることが可能である。
The timing of ingesting the composition for lowering blood alcohol concentration of the present invention is not particularly limited, and sickness and hangover can be prevented by ingesting the composition before or simultaneously with the ingestion of alcohol. In addition, it is possible to suppress sickness and hangover by taking it after ingesting alcohol.

【0015】本発明の血中アルコール濃度低下用組成物
は後述の実験例からも明らかなように、生物に対して毒
性を示さず、安全性が極めて高い。
The composition for lowering blood alcohol concentration of the present invention does not show toxicity to living organisms and is extremely high in safety, as is clear from the following experimental examples.

【0016】[0016]

【実施例】以下に実験例および実施例をあげて本発明を
詳細に説明する。 参考例1 オタネニンジン(韓国産)の根から誘導したカルスをシ
ードとして用いた。カルスは寒天を含む固形MS培地
(ムラシゲ−スクーグ培地)上で通常の培養条件で培養
された。培養液として、カイネチン0.1ppmとイン
ドール酢酸2ppmを含むMS培地を用いた。この培養
液2Lを滅菌し、これに上記シード組織の所定量を接種
した。接種量は1回目が82g、2回目が99g、3回
目が121g(いずれも湿重量)であった。これを毎分
90ストロークの往復振とう機にて25℃で2週間振と
う培養して組織培養オタネニンジンを得た。
EXAMPLES The present invention will be described below in detail with reference to experimental examples and examples. Reference Example 1 A callus derived from the root of Panax ginseng (from Korea) was used as a seed. The callus was cultured on a solid MS medium containing agar (Murashige-Skoog medium) under normal culture conditions. As a culture solution, an MS medium containing 0.1 ppm of kinetin and 2 ppm of indoleacetic acid was used. 2 L of this culture was sterilized and inoculated with a predetermined amount of the seed tissue. The inoculation amount was 82 g for the first time, 99 g for the second time, and 121 g (the wet weight for the third time). This was shake-cultured at 25 ° C. for 2 weeks with a reciprocating shaker at 90 strokes per minute to obtain tissue-cultured panax ginseng.

【0017】参考例2 参考例1で得た乾燥組織培養オタネニンジン500gを
50%エタノールに浸漬し、85℃で5時間抽出して抽
出液を得た。この抽出液を凍結乾燥して、207.5g
の抽出乾燥粉末を得た。さらに、この抽出乾燥粉末10
0gを0.5Lの水に溶解2.5Lのエタノールを攪拌
下で滴下し、不溶物をワットマンNo2濾紙で濾過して集
め、乾燥し、エタノール沈澱物48gを得た。
Reference Example 2 500 g of the dried tissue culture panax ginseng obtained in Reference Example 1 was immersed in 50% ethanol and extracted at 85 ° C. for 5 hours to obtain an extract. This extract was lyophilized to 207.5 g.
To obtain an extracted dry powder. Further, the extracted dry powder 10
0 g was dissolved in 0.5 L of water. 2.5 L of ethanol was added dropwise under stirring, and the insoluble matter was collected by filtration through Whatman No. 2 filter paper, and dried to obtain 48 g of ethanol precipitate.

【0018】実験例1 材料:参考例1に準じて調製した組織培養オタネニンジ
ン、および栽培オタネニンジンの乾燥粉末40gを80
0mlの50%エタノールで抽出し、凍結乾燥して抽出物
粉末を得た(各々41.3%、41.3%)。さらに組
織培養オタネニンジンの抽出物粉末10gを水50mlに
溶解し、エタノール250mlを攪拌しながら加え、放置
後に濾過し、沈澱を集め、エタノール沈澱物4.7gを
得た。
Experimental Example 1 Materials: Tissue-cultured Panax ginseng prepared according to Reference Example 1 and 40 g of a dry powder of a cultivated Panax ginseng were used in 80
Extraction with 0 ml of 50% ethanol and lyophilization gave extract powders (41.3%, 41.3% respectively). Further, 10 g of a tissue culture panax ginseng extract powder was dissolved in 50 ml of water, 250 ml of ethanol was added with stirring, and the mixture was filtered after standing, and the precipitate was collected to obtain 4.7 g of an ethanol precipitate.

【0019】実験方法:試験前日より24時間絶食させ
たウイスター系雄性ラット(8〜10週令)に組織培養
オタネニンジンのエタノール沈澱物3g、組織培養オタ
ネニンジンの上記50%アルコール抽出物粉末3gおよ
び栽培オタネニンジンの上記50%アルコール抽出物粉
末3gを各々15mlの水に懸濁し、体重1kg当たり5ml
を経口投与する。その直後に30%(w/v)のエタノ
ールを経口投与する。エタノール投与から、0、30、
60、90、120、180分後に無麻酔下で尾静脈か
らヘマトクリットチューブを用いて約100μl採血す
る。採取した血液を12000rpmで5分間遠心分離
する。得られた血漿20μlに0.33ml/Lの過塩素
酸580μlを添加し混和する。3000rpmで5分
間遠心分離した後、上清中のエタノール量をエタノール
測定キット(ベーリンガー・インゲルハイム山之内)を
用いて測定した。
Experimental method: Wistar male rats (8-10 weeks old) which had been fasted for 24 hours from the day before the test were subjected to 3 g of ethanol precipitate of tissue-cultured panax ginseng, 3 g of the above 50% alcohol extract powder of tissue-cultured panax ginseng, and cultivated panax ginseng 3 g of the above 50% alcohol extract powder was suspended in 15 ml of water, and 5 ml of the powder
Is orally administered. Immediately thereafter, 30% (w / v) of ethanol is orally administered. From ethanol administration, 0, 30,
After 60, 90, 120, and 180 minutes, about 100 μl of blood is collected from the tail vein using a hematocrit tube under anesthesia. The collected blood is centrifuged at 12000 rpm for 5 minutes. To 20 μl of the obtained plasma, 580 μl of 0.33 ml / L perchloric acid is added and mixed. After centrifugation at 3000 rpm for 5 minutes, the amount of ethanol in the supernatant was measured using an ethanol measurement kit (Boehringer Ingelheim Yamanouchi).

【0020】実験結果:図1に示した通りであり、組織
培養オタネニンジンのエタノール不溶物のみが極めて顕
著な血中アルコール濃度低下作用を示した。
Experimental results: As shown in FIG. 1, only the ethanol-insoluble substance of tissue culture panax ginseng showed a very remarkable blood alcohol concentration lowering effect.

【0021】実験例2 実験方法:組織培養オタネニンジンのエタノール沈澱物
の乾燥粉末を5g/kgの投与量で各々ddY系雄性マウ
ス3匹に投与し、2時間観察し急性毒性を調べた。 実験結果:組織培養オタネニンジンのエタノール沈澱物
の乾燥粉末の投与群で死亡例は認められなかった。この
ように、本発明の血中アルコール濃度低下組成物は毒性
が極めて低く安全性が高い。
Experimental Example 2 Experimental method: A dry powder of ethanol precipitate of tissue culture panax ginseng was administered at a dose of 5 g / kg to three ddY male mice, respectively, and observed for 2 hours to examine acute toxicity. Experimental results: No deaths were observed in the group administered with the dry powder of the ethanol precipitate of tissue culture ginseng. Thus, the composition for lowering blood alcohol concentration of the present invention has extremely low toxicity and high safety.

【0022】実施例1 飲料 組織培養オタネニンジンのエタノール沈澱物乾燥粉末 1g 液糖 10g 有機酸(クエン酸) 0.3g ビタミンC 1g シクロデキストリン 1g 香料 0.5ml 上記各成分を配合し、水を加えて100mlとした後加熱
殺菌して飲料製品を得た。
Example 1 Beverage Tissue cultured ethanol precipitate of Panax ginseng dry powder 1 g Liquid sugar 10 g Organic acid (citric acid) 0.3 g Vitamin C 1 g Cyclodextrin 1 g Flavor 0.5 ml Mix the above ingredients and add water. After making up to 100 ml, it was sterilized by heating to obtain a beverage product.

【0023】実施例2 顆粒剤/粉末剤 組織培養オタネニンジンのエタノール沈澱物乾燥粉末 1g 調味料 適量 シクロデキストリン 1g 上記各成分を配合し、良く混和し、粉末食品とする。ま
た、顆粒剤としては上記各成分を配合し、少量の水を加
えて練合、整粒、乾燥して調製する。以上の量を1包装
とし、1回に1〜3包装を摂取する。
Example 2 Granules / Powder Tissue-cultured Panax ginseng ethanol precipitate dry powder 1 g Seasoning appropriate amount Cyclodextrin 1 g The above ingredients are blended and mixed well to obtain a powdered food. Granules are prepared by mixing the above components, adding a small amount of water, kneading, sizing and drying. The above amount is taken as one package, and one to three packages are taken at a time.

【0024】実施例3 組織培養オタネニンジンのエタノール不溶物乾燥粉末
0.5gずつを硬カプセルに充填した。本カプセルは1
回に1〜6カプセルを摂取する。
Example 3 Hard capsules were filled with 0.5 g of a dry powder of ethanol insoluble tissue panax ginseng in ethanol. This capsule is 1
Take 1-6 capsules at a time.

【0025】[0025]

【発明の効果】本発明の組成物は有為に血中アルコール
濃度を低下させるので、飲酒による悪酔い、二日酔いを
予防・防止することが可能であり、長期的にはアルコー
ル肝炎を防止するための食品、医薬品に利用され得る。
Since the composition of the present invention significantly lowers the blood alcohol concentration, it is possible to prevent and prevent sickness and hangover caused by drinking, and to prevent alcohol hepatitis in the long term. It can be used for food and medicine.

【0026】[0026]

【文献】[Literature]

1. Ngasawa, H. T., et al.: Life Sciences vol. 20,
187, 1977 2. 森井勇、鶴見介登他:アルコール研究 vol. 11 No.
2: 12, 1974 3. Peter. C. J.: Analitical Biochem., vol. 87, 11
6, 1977 4. 特開昭58−157724号公報 5. 特開昭61−134313号公報 6. 特開平3−127739号公報 7. Eui, S. C., et al.: Korean Biochem. J.: vol.
11(1), 1, 1978 8. Lee, F. C., et al.: Clinical and Experimental
Pharmacology & Physiology : vol. 14, 543, 1987
1. Ngasawa, HT, et al .: Life Sciences vol. 20,
187, 1977 2. Isamu Morii, Keito Tsurumi et al .: Alcohol Studies vol. 11 No.
2: 12, 1974 3. Peter. CJ: Analitical Biochem., Vol. 87, 11
6, 1977 4. JP-A-58-157724 5. JP-A-61-134313 6. JP-A-3-127439 7. Eui, SC, et al .: Korean Biochem. J .: vol.
11 (1), 1, 1978 8. Lee, FC, et al .: Clinical and Experimental
Pharmacology & Physiology: vol. 14, 543, 1987

【図面の簡単な説明】[Brief description of the drawings]

【図1】本発明組成物が優れた血中アルコール濃度低下
作用を示すことを明らかにするグラフである。
FIG. 1 is a graph showing that the composition of the present invention exhibits an excellent blood alcohol concentration lowering effect.

───────────────────────────────────────────────────── フロントページの続き (56)参考文献 特開 昭60−188326(JP,A) 特開 平3−7235(JP,A) 日薬理誌,vol.93,no.4,p 261−270,1989 (58)調査した分野(Int.Cl.7,DB名) A61K 35/78 BIOSIS(DIALOG) CA(STN)──────────────────────────────────────────────────続 き Continuation of the front page (56) References JP-A-60-188326 (JP, A) JP-A-3-7235 (JP, A) Nihon Pharmaceutical Journal, vol. 93, no. 4, p 261-270, 1989 (58) Fields investigated (Int. Cl. 7 , DB name) A61K 35/78 BIOSIS (DIALOG) CA (STN)

Claims (3)

(57)【特許請求の範囲】(57) [Claims] 【請求項1】 組織培養オタネニンジンの抽出物のエタ
ノール不溶物を含有してなる血中アルコール濃度低下
Claims: 1. A decrease in blood alcohol concentration comprising an ethanol-insoluble substance of a tissue culture panax ginseng extract
Agent .
【請求項2】 組織培養オタネニンジンの抽出物が水性
溶媒による抽出物である請求項1記載の血中アルコール
濃度低下
2. The agent for lowering blood alcohol concentration according to claim 1, wherein the extract of tissue culture panax ginseng is an extract with an aqueous solvent.
【請求項3】 水性溶媒が水単独または水とエタノール
との混合溶媒である請求項2記載の血中アルコール濃度
低下
3. The agent according to claim 2, wherein the aqueous solvent is water alone or a mixed solvent of water and ethanol.
JP24675791A 1991-08-30 1991-08-30 Composition for lowering blood alcohol concentration Expired - Lifetime JP3228534B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP24675791A JP3228534B2 (en) 1991-08-30 1991-08-30 Composition for lowering blood alcohol concentration

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP24675791A JP3228534B2 (en) 1991-08-30 1991-08-30 Composition for lowering blood alcohol concentration

Publications (2)

Publication Number Publication Date
JPH05170659A JPH05170659A (en) 1993-07-09
JP3228534B2 true JP3228534B2 (en) 2001-11-12

Family

ID=17153206

Family Applications (1)

Application Number Title Priority Date Filing Date
JP24675791A Expired - Lifetime JP3228534B2 (en) 1991-08-30 1991-08-30 Composition for lowering blood alcohol concentration

Country Status (1)

Country Link
JP (1) JP3228534B2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4504118B2 (en) * 2003-06-30 2010-07-14 株式会社東洋新薬 Alcoholic beverage
KR101074158B1 (en) * 2008-04-07 2011-10-17 재단법인 한국원자력의학원 Composition comprising polysaccharide extracted from panax ginseng preventing and treating liver diseases
KR101179171B1 (en) * 2008-08-14 2012-09-03 주식회사 운화 Composition for Preventing or Treating Hepatitic Disease Comprising Plant Stem Cell Line Derived from Cambium of Panax ginseng Including Wild Ginseng or Ginseng
WO2011051742A1 (en) * 2009-10-28 2011-05-05 Modutech S.A. Preparation comprising amino acids and plants and its activity in the alcohol detoxification
CN104056238A (en) * 2014-07-10 2014-09-24 魏放 Traditional Chinese medicine preparation for protecting liver and dispelling effects of alcohol
KR101621356B1 (en) * 2014-09-05 2016-05-17 한국과학기술원 Use of ginsenoside F2 for prophylaxis and treatment of liver disease
JP2016086715A (en) * 2014-10-31 2016-05-23 アサヒグループホールディングス株式会社 Food and drink containing component derived from carrot

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
日薬理誌,vol.93,no.4,p261−270,1989

Also Published As

Publication number Publication date
JPH05170659A (en) 1993-07-09

Similar Documents

Publication Publication Date Title
JP3333777B2 (en) Acyl COA-cholesterol-O-acyl transferase inhibitor, inhibitor of macrophage-lipid complex accumulation on arterial wall, and citrus peel extract as prophylactic or therapeutic agent for liver disease
JPH08169831A (en) Agent for promoting metabolism of alcohol in body and its production
JPH08225453A (en) Lipoprotein (a) depressor, cholesterol depressor and medicine containing the same
JP3228534B2 (en) Composition for lowering blood alcohol concentration
US7767236B2 (en) Plant seed extract composition and process for producing the same
JP3334725B2 (en) Accelerator for reducing alcohol in the body, its metabolites and oral freshener
JP2001520993A (en) Acyl COA-cholesterol-O-acyltransferase inhibitors, inhibitors of macrophage-lipid complex accumulation on arterial walls and hesperidin and hesperetin as agents for preventing or treating liver diseases
JP4817087B2 (en) Bioactive extract
JP3130327B2 (en) Liver dysfunction preventive agent and functional food having hepatic dysfunction preventive action
KR20010008818A (en) The concentration of alcohol in the blood and method for producing the same
JPH08277221A (en) Suppressant for alcohol absorption
JP2010043036A (en) Saccharometabolism promoter
KR100372022B1 (en) Pharmaceutical composition for the prevention and treatment of hepatocirrhosis
JP2891738B2 (en) Alcohol absorption inhibitor
JP2006016340A (en) Blood uric acid level reduction agent having extract of punica granatum l. as active ingredient
US20040146468A1 (en) Oral compositon comprising an extract from the bark of albizzia myrioplylla
JPS60155125A (en) Agent for phenylketonuria
US20240123019A1 (en) Composition for treating or ameliorating liver disease and liver dysfunction comprising zizania latifolia extract
JPH06199693A (en) Agent for amelioration and treatment of ischemic disease
JP4712927B2 (en) Chronic hepatitis inhibitor
JP3936245B2 (en) Antihypertensive
KR0179087B1 (en) Composition containing rhodiola sachalinesis extract for lowering blood alcohol concentration
JPH0920653A (en) Dizziness suppressing agent
JP2004024104A (en) Propolis extract, method for producing the same, hypotensive agent containing the same, food preparation and propolis composition
JPH0474333B2 (en)

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (prs date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110907

Year of fee payment: 10

EXPY Cancellation because of completion of term